Research Group Metabolism (META)

Head: Dr. Rui Wang-Sattler

The META research group is studying metabolic diseases (e.g. type 2 diabetes and cardiovascular diseases). We use statistical and bioinformatical methods to integrate metabolomics, transcriptomics, epigenomics, genomics data, and information from public databases to better understand the pathophysiological mechanisms. This helps us to identify candidate biomarkers and drug targets, with the final goal to translate our discoveries into clinical practice.

Objectives and current projects:

  1. Identification of early candidate biomarkers of metabolic diseases
    •    Type 2 diabetes
    •    Cardiovascular diseases
    •    Schizophrenia
  2. Identification of novel pharmaceutical drug targets for cardiovascular disease
  3. Investigating life style factors (e.g. smoking, alcohol intake, physical activity and shift work) on metabolism
  4. Translation of novel biomarkers into clinical practice

Key funding:

  • EU FP7: Identification and validation of novel pharmaceutical drug targets for cardiovascular disease (CarTarDis)
  • DGUV: Shift work on nurse health
  • BBMRI-LPC: Biomarkers of ischemic stroke in prospective cohorts (BiStroke),
  • EIT Health: Development of a new diagnostic tool for early detection of Type 2 Diabetes (DeTecT2D)